PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: ...

Low testosterone may increase the risk of aggressive prostate cancer progression during active surveillance. Learn more about the findings.

New research has found that low testosterone levels can cause extreme progression in high-grade prostate cancer. The study ...

Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with ...

An investigator reported 10-year follow-up data from a phase 3 trial of extended vs limited pelvic lymph node dissection during radical prostatectomy.

A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...

Among men with high-risk localized prostate cancer, those receiving neoadjuvant apalutamide combination therapy had improved potency recovery by 12 months and reduced rates of positive margins ...

Long-term follow-up consistent with earlier report, a hint of benefit in high-grade diseas ...

Findings seen over three months in men with low-grade prostate cancer, hypogonadism treated with radical prostatectomy ...

Prostate-specific antigen (PSA) blood testing likely reduces the risk of death from prostate cancer, found a new review ...